RELEASE: APR is a finalist in the 2022 International Film Festival on Rare Diseases


RELEASE: APR is a finalist in the 2022 International Film Festival on Rare Diseases

GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a commercial-stage Swiss biopharmaceutical company that identifies, develops and markets novel products protected by patents in certain areas of specialty, rare and ultra-rare diseases globally, today announced that its subsidiary APR Applied Pharma Research SA ("APR") has been nominated as a finalist in the 2022 UnoSguardoRaro International Festival on Rare Diseases.

APR supports and contributes to the first and only European film festival showcasing films from around the world that address the challenges of life with a rare disease. APR's short film, Forward – Live your best life, was nominated as a finalist from more than 200 entries by an international expert jury made up of patient associations, healthcare professionals and filmmakers. During the awards ceremony, the jury awarded the APR film two awards: Special Mention for Best Campaign and Best Director.

"With our Live your best life! campaign, we highlight the emotional journey families with PKU go through, their difficulties juggling a strict diet and protein substitutes, and their quest to reach their full potential in life," said Paolo Galfetti , CEO of APR, whose true story of becoming a parent of a child with PKU inspired the film. Paolo Galfetti commented on APR's work for his first son, Riccardo, born with this disease: "Knowing that these products can be useful for patients and families living with this rare disease, as well as for healthcare professionals, is our greatest rewarded. I am proud to work with passionate people and the results we have achieved together. Being so involved both personally and professionally makes me even more proud of my son and the determined and energetic young man he has become."

APR's ambition to create a product that can respond to the needs of PKU patients resulted in the creation of the PKU GOLIKE® line, a food for special medical purposes. APR's experience in the identification and application of pharmaceutical technologies to improve the efficacy and tolerability of the molecules for common pathologies served as a basis to improve the absorption of the amino acid and allow better metabolic management.

As part of its participation in the festival, APR attended events in Berlin (Il Kino), Rome (Casa del Cinema) and Milan (Niguarda hospital). The festival gained the support of many rare disease associations such as:

· Eurordis - Rare Disease Europe

· link

· Uniamo - Italian Federation of Rare Diseases


PKU GOLIKE® is a phenylalanine-free food intended for the dietary treatment of phenylketonuria ("PKU"). The product is made up of a blend of amino acids in the form of granules and is available in convenient packs and medical food bars. Designed with Relief's patented Physiomimic™ technology platform, PKU GOLIKE® is the first extended-release amino acid product, characterized by a special coating that guarantees the physiological absorption of amino acids, mirroring that of natural proteins. In addition, the special coating masks the unpleasant taste, smell and aftertaste of amino acids. PKU GOLIKE® has been on the market in the EU since 2019 and was launched in the US in October 2022.

About Relief

Relief is a commercial-stage Swiss biopharmaceutical company focused on the identification, development, and commercialization of new patent-protected products for the treatment of rare and ultra-rare diseases, including metabolic disorders, lung diseases, and connective tissue disorders. Relief's diversified product portfolio consists of actives that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE®, designed with patented physiomimic technology, which is the first commercialized extended-release amino acid product for dietary management. of phenylketonuria ("PKU"). Relief has a collaborative and licensing agreement with Acer Therapeutics for the development and worldwide commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (" UCD") and maple syrup urine disease ("MSUD"). Relief is also continuing to develop aviptadil for several rare pulmonary indications. In addition, Relief is clinically developing APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa ("EB"), a group of rare, genetic, and life-threatening connective tissue disorders; APR-TD011 has received orphan drug designation from the US Food and Drug Administration. Relief is marketing various legacy products through licensing and distribution partners.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and is listed in the United States on the OTCQB under the symbols RLFTF and RLFTD.

For more information, visit Follow Relief on LinkedIn.


This communication contains, expressly or implicitly, certain forward-looking statements regarding RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including risks discussed in RELIEF THERAPEUTICS Holding SA's filings with SIX and the Securities and Exchange Commission, which could cause the results, condition RELIEF THERAPEUTICS Holding SA's actual financial situation, performance or achievements are materially different from the future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any of the forward-looking statements contained herein as a result of new information, future events or for any other reason.

Photo - link

View original content: enlace